Differential cholinergic and non-cholinergic actions of acetylcholinesterase in the substantia nigra revealed by fasciculin-induced inhibition.
The effects of the peptide fasciculin (FAS), a potent inhibitor of acetylcholinesterase (AChE) have been examined, following unilateral microinfusion, on tissue levels of monoamines in the rat substantia nigra and concomitant circling behaviour. Although FAS inhibited 87% of total AChE, the levels of dopamine and its metabolites remained unchanged. Furthermore, the treatment induced modest contraversive rotation which was markedly enhanced in the presence of a systemic challenge with apomorphine. This behavioural effect of FAS was partially reversed by systemically administered atropine. Any possible interaction of FAS with nigral dopamine systems was further investigated by testing the peptide in animals that five days earlier had undergone a 6-hydroxydopamine (6-OHDA) lesion of the SN such that dopamine and AChE were significantly but not completely reduced. In a majority of these animals, FAS treatment caused a reversal of the lesion induced ipsiversive rotation, ie restored contraversive rotation. It is concluded that in the SN, FAS can have biochemical and behavioural actions independent of local dopamine systems and linked to cholinergic transmission. In addition, treatment with FAS in the substantia nigra also reveals the possible existence of at least two distinct pools of AChE with, respectively, non-cholinergic and cholinergic actions.
Dajas
F
F
Neurochemistry Division, IIBCE, Montevideo, Uruguay.
Silveira
R
R
Costa
G
G
Castello
M E
ME
Jerusalinsky
D
D
Medina
J
J
Levesque
D
D
Greenfield
S
S
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000110:Acetylcholinesterase / Q000378:metabolism*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001679:Biogenic Amines / Q000378:metabolism*; D002462:Cell Membrane / Q000201:enzymology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004546:Elapid Venoms / Q000494:pharmacology*; D007839:Functional Laterality; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000378:metabolism; D016627:Oxidopamine; D051381:Rats; D011919:Rats, Inbred Strains; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism; D012399:Rotation; D012701:Serotonin / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*
D001679:Biogenic Amines; D002800:Cholinesterase Inhibitors; D004546:Elapid Venoms; D011976:Receptors, Muscarinic; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; C044937:fasciculin; D016627:Oxidopamine; D000110:Acetylcholinesterase; D001058:Apomorphine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid